These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 7505970

  • 21. [Finasteride (Proscar) for benign prostatic hypertrophy].
    Matzkin H, Chen J, Braf Z.
    Harefuah; 1993 Dec 15; 125(12):453-6, 496. PubMed ID: 7509305
    [Abstract] [Full Text] [Related]

  • 22. An economic evaluation of doxazosin, finasteride and combination therapy in the treatment of benign prostatic hyperplasia.
    McDonald H, Hux M, Brisson M, Bernard L, Nickel JC.
    Can J Urol; 2004 Aug 15; 11(4):2327-40. PubMed ID: 15380054
    [Abstract] [Full Text] [Related]

  • 23. The relationship among lower urinary tract symptoms, prostate specific antigen and erectile dysfunction in men with benign prostatic hyperplasia: results from the proscar long-term efficacy and safety study.
    Paick SH, Meehan A, Lee M, Penson DF, Wessells H.
    J Urol; 2005 Mar 15; 173(3):903-7. PubMed ID: 15711315
    [Abstract] [Full Text] [Related]

  • 24. [PSA values before and after finasteride treatment in patients with benign prostatic hypertrophy].
    Trinchieri A, Dell'Orto P.
    Arch Ital Urol Androl; 1995 Feb 15; 67(1):33-5. PubMed ID: 7538385
    [Abstract] [Full Text] [Related]

  • 25. Comparative effect of finasteride and dutasteride on chromogranin A levels.
    Sciarra A, Salciccia S, Nesi G, Cattarino S, Alfarone A, Gentilucci A, Gentile V.
    Anticancer Res; 2010 Nov 15; 30(11):4737-42. PubMed ID: 21115933
    [Abstract] [Full Text] [Related]

  • 26. 5alpha-reductase inhibitors/finasteride.
    Stoner E.
    Prostate Suppl; 1996 Nov 15; 6():82-7. PubMed ID: 8630236
    [Abstract] [Full Text] [Related]

  • 27. [Specific antigen prostatic changes during treatment with finasteride or dutasteride for benign prostatic hyperplasia].
    Arena F.
    Minerva Urol Nefrol; 2013 Sep 15; 65(3):211-6. PubMed ID: 23872632
    [Abstract] [Full Text] [Related]

  • 28. Endocrine therapy for benign prostatic hyperplasia in the 90's.
    Ekman P.
    J Urol (Paris); 1995 Sep 15; 101(1):22-5. PubMed ID: 7545721
    [Abstract] [Full Text] [Related]

  • 29. Effects of finasteride on prostate volume and prostate-specific antigen.
    Chiu KY, Yong CR.
    J Chin Med Assoc; 2004 Nov 15; 67(11):571-4. PubMed ID: 15720071
    [Abstract] [Full Text] [Related]

  • 30. Pharmacological treatment of benign prostatic hyperplasia with finasteride: a clinical review.
    Ekman P.
    Arch Esp Urol; 1994 Nov 15; 47(9):883-7; discussion 887-8. PubMed ID: 7530944
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. [Effect of dutasteride on reduction of plasma DHT following finasteride therapy in patients with benign prostatic hyperplasia].
    Botto H, Lan O, Poulain JE, Comenducci A.
    Prog Urol; 2005 Dec 15; 15(6):1090-5. PubMed ID: 16429658
    [Abstract] [Full Text] [Related]

  • 34. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group.
    Roehrborn CG, McConnell JD, Lieber M, Kaplan S, Geller J, Malek GH, Castellanos R, Coffield S, Saltzman B, Resnick M, Cook TJ, Waldstreicher J.
    Urology; 1999 Mar 15; 53(3):473-80. PubMed ID: 10096369
    [Abstract] [Full Text] [Related]

  • 35. Effect of finasteride on bother and other health-related quality of life aspects associated with benign prostatic hyperplasia. PLESS Study Group. Proscar Long-term Efficacy and Safety Study.
    Bruskewitz R, Girman CJ, Fowler J, Rigby OF, Sullivan M, Bracken RB, Fusilier HA, Kozlowski D, Kantor SD, Johnson EL, Wang DZ, Waldstreicher J.
    Urology; 1999 Oct 15; 54(4):670-8. PubMed ID: 10510926
    [Abstract] [Full Text] [Related]

  • 36. Therapeutic effects of finasteride in benign prostatic hyperplasia: a randomized double-blind controlled trial.
    Yu HJ, Chiu TY, Lai MK.
    J Formos Med Assoc; 1995 Oct 15; 94(1-2):37-41. PubMed ID: 7542109
    [Abstract] [Full Text] [Related]

  • 37. Effect of finasteride on free and total serum prostate-specific antigen in men with benign prostatic hyperplasia.
    Matzkin H, Barak M, Braf Z.
    Br J Urol; 1996 Sep 15; 78(3):405-8. PubMed ID: 8881951
    [Abstract] [Full Text] [Related]

  • 38. Prostate tissue composition and response to finasteride in men with symptomatic benign prostatic hyperplasia.
    Marks LS, Partin AW, Gormley GJ, Dorey FJ, Shery ED, Garris JB, Subong EN, Stoner E, deKernion JB.
    J Urol; 1997 Jun 15; 157(6):2171-8. PubMed ID: 9146609
    [Abstract] [Full Text] [Related]

  • 39. Finasteride for the treatment and control of benign prostatic hyperplasia: summary of phase III controlled studies. The Finasteride Study Group.
    Grino P, Stoner E.
    Eur Urol; 1994 Jun 15; 25 Suppl 1():24-8. PubMed ID: 7507052
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.